Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
p53 Peptide Vaccine in Ovarian Cancer
NCT00001827Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jul 1999
- Primary completion
- Dec 2007
- Modality
- Whole Cell Cancer Vaccines, Peptides, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of p53 peptide-loaded dendritic cell vaccine (University of Pittsburgh) in Malignant Ovarian Tumor, sponsored by National Cancer Institute. Started Jul 1999; status: terminated.
02
Drugs
p53 peptide-loaded dendritic cell vaccine (University of Pittsburgh)
03
Conditions
Malignant Ovarian Tumor
Beyond the preview
Go deeper on NCT00001827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001827.